Once-Weekly Paclitaxel Remains Preferred for Advanced Breast Cancer

Share this content:
Paclitaxel once per week remains the preferred palliative chemotherapy in patients with chemotherapy-naive advanced breast cancer.
Paclitaxel once per week remains the preferred palliative chemotherapy in patients with chemotherapy-naive advanced breast cancer.

Paclitaxel once per week remains the preferred palliative chemotherapy in patients with chemotherapy-naive advanced breast cancer, a new study published online ahead of print in the Journal of Clinical Oncology has shown.

For the phase III trial, researchers enrolled 799 patients with chemotherapy-naive advanced breast cancer and randomly assigned them to receive bevacizumab plus paclitaxel 90 mg/m2 (arm A), nab-paclitaxel 150 mg/m2 (arm B), or ixabepilone 16 mg/m2 (arm C), once weekly for 3 weeks of each 4-week cycle. Of those, 783 patients received treatment.

At the time of first interim analysis, arm C was closed for futility. Arm A and arm B were closed for futility at the second interim analysis.

Results showed that median progression-free survival for paclitaxel was 11 months versus 7.4 months for ixabepilone (HR = 1.59; 95% CI: 1.31, 1.93; P < 0.001) and 9.3 months for nab-paclitaxel (HR = 1.20; 95% CI: 1.00, 1.45; P = 0.054).

RELATED: Study Detects Novel Genetic Markers of Breast Cancer Survival

Therefore, ixabepilone weekly was inferior to paclitaxel, and nab-paclitaxel was not superior to paclitaxel with a trend toward inferiority.

In regard to safety, patients who received nab-paclitaxel experienced a higher incidence of hematologic and non-hematologic toxicity, including peripheral neuropathy. Patients in that group also had more frequent and earlier dose reductions.

Reference

  1. Rugo HS, Barry WT, Moreno-Aspita A, et al. Randomized phase III trial of paclitaxel once per week compared with nanoparticle albumin-bound nab-paclitaxel once per week or ixabepilone for locally recurrent or metastatic breast cancer: CALGB 40502/NCCTG N063H (Alliance). J Clin Oncol. 2015. [Epub ahead of print]. doi: 10.1200/JCO.2014.59.5298.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs